Skip to main content

Table 1 Basic characteristics of the studies included in this meta-analysis

From: Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review

Study Regimen PN Area TP TG Patient
Bang Y. J 2010 [7] Trastuzumab + fluoropyrimidine + cisplatin 294 worldwide FL EGFR Selected
fluoropyrimidine-cisplatin 290
Wilke H 2014 [8] Ramucirumab + paclitaxel 330 Asia SL VEGFR Unselected
Placebo + paclitaxel 335
Shen L 2015 [9] Bevacizumab + Cisplatin + Capecitabine 100 Asia FL VEGFR Unselected
Placebo + Cisplatin + Capecitabine 102
Lordick F 2013 [10] Cetuximab + Capecitabine + cisplatin 455 worldwide FL EGFR Unselected
Capecitabine + cisplatin 449
Waddell T 2013 [12] Panitumumab + mEOC 278 Europe FL EGFR Unselected
Epirubicin + Capecitabine + oxaliplatin 275
Rao S 2010 [13] matuzumab + Epirubicin + Capecitabine + cisplatin 35 Europe FL EGFR Selected
Epirubicin + Capecitabine + cisplatin 36
NCT01246960 [15] Ramucirumab + Oxaliplatin + Leucovorin + 5-Fu 84 N FL VEGFR Unselected
Placebo + Oxaliplatin + Leucovorin + 5-Fu 84
Ohtsu A 2011 [16] Bevacizumab + fluoropyrimidine + cisplatin 387 worldwide FL VEGFR Unselected
Placebo + fluoropyrimidine-cisplatin 387
Du F 2015 [17] Nimotuzumab + S-1 + Cisplatin 31 Asia FL EGFR Unselected
S-1 + Cisplatin 31
Koizumi W 2013 [18] TSU-68 + S-1 + cisplatin 45 Asia FL VEGFR Unselected
S-1 + cisplatin 46
Satoh T 2015 [19] Nimotuzumab + irinotecan 40 Asia SL EGFR Unselected
Irinotecan 42
Satoh T 2014 [20] lapatinib + paclitaxel 132 Asia SL EGFR Selected
Paclitaxe 129
Yi J. H 2012 [21] Sunitinib + docetaxel 56 Asia SL VEGFR Unselected
Docetaxel 49
Hecht J. R 2016 [22] Lapatinib + Capecitabine + Oxaliplatin 272 worldwide FL EGFR Selected
Placebo + Capecitabine + Oxaliplatin 273
  1. PN patient number, TP treatment plan, TG the targeted gene, FL first-line, SL second-line, Selected the EGFR-positive, unselected the whole patients, N unknown